MX2022001520A - Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos. - Google Patents
Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos.Info
- Publication number
- MX2022001520A MX2022001520A MX2022001520A MX2022001520A MX2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A MX 2022001520 A MX2022001520 A MX 2022001520A
- Authority
- MX
- Mexico
- Prior art keywords
- hexadienoates
- opioid
- hexadienoate
- modification
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885311P | 2019-08-11 | 2019-08-11 | |
| US16/540,058 US11186585B2 (en) | 2018-08-17 | 2019-08-14 | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
| PCT/US2020/021599 WO2021029914A1 (en) | 2019-08-11 | 2020-03-07 | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001520A true MX2022001520A (es) | 2022-07-21 |
Family
ID=74571142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001520A MX2022001520A (es) | 2019-08-11 | 2020-03-07 | Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4010078A4 (enExample) |
| JP (1) | JP7535569B2 (enExample) |
| CN (1) | CN114828961B (enExample) |
| CA (1) | CA3149152A1 (enExample) |
| MX (1) | MX2022001520A (enExample) |
| WO (1) | WO2021029914A1 (enExample) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668685A (en) | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| EP0615756B1 (en) * | 1993-03-15 | 2001-06-27 | National Science Council | Nalbuphine esters and long-acting pharmaceutical compositions containing them |
| CN1050130C (zh) | 1997-07-04 | 2000-03-08 | 卢正堂 | 纳洛酮酸脂和纳屈酮酸脂及系列物和制备方法 |
| EP1149836B1 (en) | 2000-04-27 | 2003-02-26 | Oliver Yoa-Pu Hu | Polynalbuphine derivatives |
| TWI226239B (en) | 2000-05-15 | 2005-01-11 | You-Pu Hu | Novel oral pharmaceutical composition containing nalbuphine ester prodrug |
| CA2771263A1 (en) | 2000-07-27 | 2002-02-07 | Rutgers, The State University | Therapeutic polyesters and polyamides |
| US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
| US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| WO2005009377A2 (en) | 2003-07-23 | 2005-02-03 | University Of Kentucky Research Foundation | Novel oral bioavailable prodrugs |
| US20050137141A1 (en) | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
| WO2007022535A2 (en) | 2005-08-19 | 2007-02-22 | Pharmacofore, Inc. | Prodrugs of active agents |
| WO2009092071A2 (en) | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof |
| KR20110134510A (ko) | 2009-04-02 | 2011-12-14 | 샤이어 엘엘씨 | 오피오이드의 신규한 디카르복실산 연결 아미노산 및 펩티드 프로드러그와 그 용도 |
| WO2011007247A1 (en) | 2009-07-17 | 2011-01-20 | Llc Shire | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
| CA2768392C (en) | 2009-07-21 | 2018-04-17 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US20110190267A1 (en) * | 2010-01-05 | 2011-08-04 | Shire Pharmaceuticals, Inc. | Prodrugs of opioids and uses thereof |
| US8461171B2 (en) | 2010-02-09 | 2013-06-11 | QRxPharma Ltd. | Hybrid opioid compounds and compositions |
| JP5941038B2 (ja) * | 2010-04-02 | 2016-06-29 | ジネルバ ファーマシューティカルズ， インコーポレイティド | 経皮送達可能なオピオイドプロドラッグ、乱用抵抗性組成物及びオピオイドプロドラッグを使用する方法 |
| JP5864606B2 (ja) | 2010-12-28 | 2016-02-17 | ユーロ−セルティーク エス．エイ． | パーキンソン病の治療におけるオピオイド作動薬とオピオイド拮抗薬との組合せ |
| US9987269B2 (en) | 2015-04-27 | 2018-06-05 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof |
| US10449190B2 (en) * | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
| US10017519B2 (en) * | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
| WO2017037813A1 (ja) * | 2015-08-29 | 2017-03-09 | 株式会社メドレックス | 塩基性薬物とソルビン酸とを含有する経皮吸収組成物 |
| US12590065B2 (en) | 2017-04-14 | 2026-03-31 | Zevra Therapeutics, Inc. | Levorphanol prodrugs and processes for making and using them |
| US11186585B2 (en) * | 2018-08-17 | 2021-11-30 | Kappa-Pharma LLC | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
-
2020
- 2020-03-07 EP EP20852037.9A patent/EP4010078A4/en active Pending
- 2020-03-07 JP JP2022509137A patent/JP7535569B2/ja active Active
- 2020-03-07 MX MX2022001520A patent/MX2022001520A/es unknown
- 2020-03-07 WO PCT/US2020/021599 patent/WO2021029914A1/en not_active Ceased
- 2020-03-07 CN CN202080071185.9A patent/CN114828961B/zh active Active
- 2020-03-07 CA CA3149152A patent/CA3149152A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114828961B (zh) | 2024-03-29 |
| EP4010078A4 (en) | 2023-08-09 |
| WO2021029914A1 (en) | 2021-02-18 |
| CN114828961A (zh) | 2022-07-29 |
| JP7535569B2 (ja) | 2024-08-16 |
| CA3149152A1 (en) | 2021-02-18 |
| EP4010078A1 (en) | 2022-06-15 |
| JP2022544564A (ja) | 2022-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX370608B (es) | Compuestos de morfinano. | |
| MX361542B (es) | Compuestos de morfinan. | |
| RU2009125597A (ru) | Пролекарства и способы их получения и применения | |
| MX2009010378A (es) | Metodos para tratar o prevenir el vomito utilizando secretagogos de hormona de crecimiento. | |
| YU98902A (sh) | Derivati aza premošćenih bicikličnih amino kiselina kao antagonisti alfa4 integrina | |
| DK1554282T3 (da) | Morphinanderivater substitueret i position 14 og deres kvaternære ammoniumsalte, fremstillingsmetode og anvendelse | |
| MXPA05003104A (es) | Hidromorfonas n-sustituidas y uso de las mismas. | |
| IL164787A0 (en) | Tachykinin receptor antagonists | |
| IL166298A0 (en) | 8-hydroxy quinoline derivatives | |
| AR042463A1 (es) | Tratamiento del dolor con combinaciones de nalbufina y agonistas del receptor de opioides kappa y antagosnistas del receptor opioides | |
| UA96777C2 (ru) | Фенилпропионамидные соединения и их применение как опиоидных агонистов | |
| ATE388707T1 (de) | Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen | |
| WO2006020930A3 (en) | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | |
| WO2007146758A3 (en) | Novel mch receptor antagonists | |
| UA89192C2 (ru) | Производные пиролопиримидина и пиролопиридина, замещенные циклической аминогруппой, как антагонисты crf | |
| HRP20130614T1 (en) | Novel pyrazole-substituted arylamides | |
| EA030609B8 (ru) | Композиции бупренорфина и антагонистов мю-опиоидных рецепторов | |
| AR077394A1 (es) | Metodos para tratar nvpa ynvpo con composiciones de ondansetron de liberacion prolongada | |
| MXPA03007885A (es) | Norbuprenorfina n-but-3-enilo y metodos de uso. | |
| SI1828177T1 (sl) | Novi antagonisti mch receptorja | |
| WO2005040157A3 (en) | Novel mch receptor antagonists | |
| MX2009008561A (es) | Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. | |
| MX385316B (es) | Compuestos de morfinano. | |
| EP1988075A4 (en) | PYRROLE DERIVATIVE OR SALT THEREOF | |
| EP4616915A3 (en) | Ecopipam for treatment of tourettes syndrome |